Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus

BACKGROUND: The relationship between cell-bound complement activation products (CB-CAPs: EC4d, EC3d), anti-C1q, soluble complement C3/C4 and disease activity in systemic lupus erythematosus (SLE) was evaluated. METHODS: Per protocol, at baseline all SLE subjects enrolled in this longitudinal study p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lupus Sci Med
Hlavní autoři: Buyon, Jill, Furie, Richard, Putterman, Chaim, Ramsey-Goldman, Rosalind, Kalunian, Kenneth, Barken, Derren, Conklin, John, Dervieux, Thierry
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2016
Témata:
Biomarker Studies
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5051407/
https://ncbi.nlm.nih.gov/pubmed/27752336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/lupus-2016-000165
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky